Ralexar Therapeutics ralexar.com


Public lists: Pharma Startups (6570)

Ralexar Therapeutics is a privately held specialty pharmaceutical company developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis.

Ralexar Therapeutics is a privately held specialty pharmaceutical company developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR...Show all

Company (Alive / Active)

Phone: 484-318-2988

Fax:

640 Lee Road
Suite 118
Wayne, 19087
Pennsylvania, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Ralexar Therapeutics $27.5M Jan 4, 2019

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Ralexar Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Third PointHedge FundNew York, New York, United States
New Science VenturesVenture CapitalNew York, New York, United StatesSeries A - III, Series A - II, Series A
Palo Alto InvestorsOtherPalo Alto, California, United StatesSeries A
The Michael J. Fox FoundationNon-Profit FoundationNew York, New York, United StatesGrant
Third Point VenturesCorporate VentureMenlo Park, California, United StatesSeries A - III, Series A - II, Series A
See all 5 investors
There is no Competitors data available for this company. Please select another tab.